WATERTOWN, Mass.--(BUSINESS WIRE)--Apr. 30, 2019--
Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company
focused on developing and commercializing novel tetracyclines to treat
serious and life-threatening conditions, today announced that senior
management will be participating at the SunTrust Robinson Humphrey 5th
Annual Life Sciences Summit on Tuesday, May 7, 2019 at the Lotte New
York Palace Hotel in New York City. Guy Macdonald, President and Chief
Executive Officer of Tetraphase, will also present a corporate overview
at the UBS Global Healthcare Conference on Monday, May 20, 2019 at 1:30
p.m. ET at the Grant Hyatt Hotel in New York City.
A live audio webcast of the UBS Global Healthcare Conference
presentation will be available on the Company’s website at https://tphase.gcs-web.com/events-presentations.
The archived presentation will be available for 30 days.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc., is a biopharmaceutical company using
its proprietary chemistry technology to create novel tetracyclines for
serious and life-threatening conditions, including infections caused by
many of the multidrug-resistant bacteria highlighted as urgent public
health threats by the World Health Organization and the Centers for
Disease Control and Prevention. The Company has created more than 3,000
novel tetracycline compounds using its proprietary technology platform.
Tetraphase's lead product XERAVATM is approved for the
treatment of complicated intra-abdominal infections by the U.S. Food and
Drug Administration and the European Medicines Agency. The Company’s
pipeline also includes TP-271 and TP-6076, which are in Phase 1 clinical
trials, and TP-2846, which is in preclinical testing for acute myeloid
leukemia. Please visit www.tphase.com
for more company information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190430005033/en/
Source: Tetraphase Pharmaceuticals, Inc.
Media and Investor Contact: